49827-15-8

Usage

Uses

Used in Pharmaceutical Industry:
IODO-ACETIC ACID TERT-BUTYL ESTER is used as a synthetic intermediate for the development of water-soluble derivatives of potent V-ATPase inhibitors, such as archazolid. This application is significant because V-ATPase inhibitors have potential therapeutic applications in various diseases, including cancer and neurodegenerative disorders.
Used in Biological Evaluation:
In the field of biological research, IODO-ACETIC ACID TERT-BUTYL ESTER serves as a key compound in the synthesis and evaluation of water-soluble V-ATPase inhibitors. These inhibitors can be assessed for their potential effects on cellular processes and their therapeutic potential in treating specific diseases.

Upstream product

• 107-59-5 tert-Butyl chloroacetate 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 1207973-75-8 lithium tert-butyl acetate 
• 153851-06-0 tert-butyl (2-hydroxy-5-methyltetrahydrofuran-2-yl)acetate 
• 70030-41-0 tert-butyl 2-(2-hydroxytetrahydrofuran-2-yl)acetate 

Downstream Products

• 86302-43-4 (tert-Butoxycarbonylmethylene)triphenylphosphorane 
• 171557-07-6 (R)-2-(Bis-tert-butoxycarbonylmethyl-amino)-propionic acid benzyl ester 
• 263716-54-7 (4R)-4-(diphenylmethyl)-3-[[(2S)-2-(tert-butyloxycarbonyl)methyl-3-(3'-methoxyphenyl)]propanoyl]-2-oxazolidinone 
• 5397-27-3 tert-butyl 3-hydroxy-3-phenylpropionate 

Relevant academic research and scientific papers

Synthesis and biological evaluation of a water-soluble derivative of the potent V-ATPase inhibitor archazolid

The water-solubility of the highly potent V-ATPase inhibitors archazolid A and the glucosylated derivative archazolid C was studied in the presence of a wide range of cosolvents, revealing very low solubilites. The first water-soluble analogue was then designed, synthesized, and evaluated for V-ATPase inhibitory activity in vitro.

TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.

Synthesis of Kainoids and C4 Derivatives

A unified stereoselective synthesis of 4-substituted kainoids is reported. Four kainic acid analogues were obtained in 8-11 steps with up to 54% overall yields. Starting from trans-4-hydroxy-l-proline, the sequence enables a late-stage modification of C4 substituents with sp2 nucleophiles. Stereoselective steps include a cerium-promoted nucleophilic addition and a palladium-catalyzed reduction. A 10-step route to acid 21a was also established to enable ready functionalization of the C4 position.

A natural product scurfpea and its enantiomer asymmetric synthetic method

The invention discloses a natural product fructus psoraleae phenol and an asymmetric synthesis method of an enantiomer thereof, belongs to the field of chemical synthesis, relates to a chemical synthesis technology, and particularly relates to a natural product Bakuchoil with optical activity and a preparation method of the enantiomer ent-Bakuchoil of the natural product. According to the method disclosed by the invention, tiglic acid and tert-butyl acetate which are easily available industrially are taken as initial raw materials to synthesize a key midbody compound 11, subsequently based of the key midbody, the natural product Bakuchoil with optical activity and the enantiomer ent-Bakuchoil thereof can be respectively synthesized by two short synthesis strategies. The method disclosed by the invention is simple to operate, convenient in separation operation, high in yield and good in selectivity, and the used reagents are all common reagents.

Δ3 Asymmetric synthesis method -2 - hydroxyl psoralen and analogue compound

The invention belongs to the field of chemical synthesis, provides a novel method for synthesizing delta3-2-hydroxybakuchiol and particularly relates to an asymmetric synthesis method for delta3-2-hydroxybakuchiol and analog compounds. The delta3-2-hydroxybakuchiol and the analog compounds, the general formula of which is (I), are synthesized by an asymmetric synthesis route. Problems in the prior art, that the content of the delta3-2-hydroxybakuchiol obtained by extraction and separation from plants is very low, an extraction rate is very low, the delta3-2-hydroxybakuchiol is prone to oxidative deterioration in extraction and separation processes, and the like, are overcome by the method. The method can provide sufficient samples for related pharmaceutical research, and provides good foundations for pharmaceutical research on antibiosis, infection resistance, oxidation resistance, pigment deposition resistance, reduction of bone loss, immunosuppression, liver damage, sedation and hypnosis, and the like. In the formula (I), R1 is selected from 4-hydroxy, 3-hydroxy, 2-hydroxy, hydrogen, 4-methyl, 4-methoxy, 4-trifluoromethyl, 3,4-[d][1,3]dioxole, and 3,4-phenyl; R2 is selected from methyl, ethyl, and butyl; and R3 is selected from vinyl, ethyl and cyclopropyl.

Novel double prodrugs of the iron chelator N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED): Synthesis, characterization, and investigation of activation by chemical hydrolysis and oxidation

The development of iron chelators suitable for the chronic treatment of diseases where iron accumulation and subsequent oxidative stress are implicated in disease pathogenesis is an active area of research. The clinical use of the strong chelator N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED) and its alkyl ester prodrugs has been hindered by poor oral bioavailability and lack of conversion to the parent chelator, respectively. Here, we present novel double prodrugs of HBED that have the carboxylate and phenolate donors of HBED masked with carboxylate esters and boronic acids/esters, respectively. These double prodrugs were successfully synthesized as free bases (7a-f) or as dimesylate salts (8a-c,e), and were characterized by 1H, 13C, and 11B NMR; MP; MS; and elemental analysis. The crystal structure of 8a was solved. Three of the double prodrugs (8a-c) were selected for further investigation into their abilities to convert to HBED by stepwise hydrolysis and H2O2 oxidation. The serial hydrolysis of the pinacol and methyl esters of N,N'-bis(2-boronic acid pinacol ester benzyl)ethylenediamine-N,N'-diacetic acid methyl ester dimesylate (8a) was verified by LC-MS. The macro half-lives for the hydrolyses of 8a-c, measured by UV, ranged from 3.8 to 26.3 h at 37 °C in pH 7.5 phosphate buffer containing 50% MeOH. 9, the product of hydrolysis of 8a-c and the intermediate in the conversion pathway, showed little-to-no affinity for iron or copper in UV competition experiments. 9 underwent a serial oxidative deboronation by H2O2 in N-methylmorpholine buffer to generate HBED (k Combining double low line 10.3 M-1min-1). The requirement of this second step, oxidation, before conversion to the active chelator is complete may confer site specificity when only localized iron chelation is needed. Overall, these results provide proof of principle for the activation of the double prodrugs by chemical hydrolysis and H2O2 oxidation, and merit further investigation into the protective capabilities of the prodrugs against H2O2-induced cell death.

DNA-templated synthesis of trimethine cyanine dyes: A versatile fluorogenic Reaction for sensing G-quadruplex formation

(Figure Presented) A healthy glow: Fluorogenic peptide nucleic acids (PNAs) functionalized with indoline derivatives are used to specifically sense G-quadruplex formation. Upon hybridization of both PNAs to the singlestranded flanking arms of quadruplex DNA (see scheme), the synthesis of a trimethine cyanine dye is templated. Dye formation can be detected by the appearance of a characteristic fluorescence signal.

Design and concise synthesis of fully protected analogues of L-γ-carboxyglutamic acid

The design and synthesis of four nonnaturally occurring amino acid analogues of L-γ-carboxyglutamic acid (Gla), appropriately protected for Fmoc-based solid-phase peptide synthesis (SPPS), is described. These amino acids are Bu-Mal 2, BCAH 3, Pen-Mal 4, a

Double diastereoselective intramolecular cyclopropanation to P-chiral [3.1.0]-bicyclic phosphonates

(Matrix Presented) A double diastereotopic differentiation strategy on a phosphonoacetate template is described. The approach utilizes Rh2(OAc)4-catalyzed intramolecular cyclopropanation (ICP) employing the (R)-pantolactone auxiliary in the ester functionality of the phosphonoacetate. The olefinic diastereofacial selectivity is governed by inherent electronic and steric interactions in the reacting carbene intermediate, while the group selectivity is dictated by the chiral auxiliary. This approach is being developed as an effective method to access bicyclic P-chiral phosphonates.

BENZOTHIAZEPINE AND BENZOXAZEPINE DERIVATIVES AS CHOLECYSTOKININ RECEPTOR ANTAGONISTS

The present invention relates to novel substituted benzothiazepines and benzoxazepines of the formula STR1 wherein R 1, R 2, R. sup. 7, R 8, R 9 and X are as defined below, and to novel intermediates used in the synthesis of such compounds. Such compounds are useful in the treatment and prevention of gastrointestinal disorders, pain and anxiety disorders.